Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 27, 2007 Brian Lawler	Jumpstarting Genzyme A great quarter for Genzyme. All three of its top products had double-digit percentage sales gains; operating margins are up too.
The Motley Fool January 9, 2008 Brian Lawler	Tracking Genzyme The biopharma updates investors on what to expect for 2008.
The Motley Fool April 24, 2008 Brian Lawler	FDA Stings Genzyme Earnings A nasty surprise hurts the drug developer's first quarter results.
The Motley Fool July 12, 2006 Brian Lawler	Genzyme Continues to Deliver The biopharmaceutical company releases their second quarter earnings announcement. The stock is up sharply today, almost 8%, after Genzyme reported earnings of $0.68 a share.
The Motley Fool April 20, 2006 John Bluis	Investors Jump Ship at Genzyme Clearly, Genzyme continues to invest in its business for the long term. That's the type of approach that can create a steady stream of market-beating returns for investors if they're willing to trust management.
The Motley Fool October 12, 2006 Brian Lawler	Genzyme Runs a Tight Ship Revenues are up at the biopharmaceutical company, but shares dropped in morning trading.
The Motley Fool May 30, 2007 Brian Lawler	Genzyme Gobbles Up a Partner Another day, another biotech acquisition for drugmaker Genzyme. Investors, with more than $500 million in free cash flow last year alone, Genzyme has money to spare.
The Motley Fool September 27, 2006 Brian Lawler	Enormous Interest in AnorMED Genzyme and Millenium vie to purchase the Canadian biotech. Shares of AnorMED currently trade for more than $12 a share.
The Motley Fool November 14, 2007 Brian Lawler	Genzyme Zigs, Shares Zag Genzyme gets downbeat news that will delay the launch of its lead drug, but shares rise. Investors, take note.
The Motley Fool April 16, 2004 Charly Travers	Genzyme's Minor Disappointment The latest sales figures for Genzyme's newest drug, Aldurazyme, show that a potential growth-driving drug may be stalling out.
The Motley Fool February 4, 2008 Brian Lawler	Genzyme Tells It Like It Is Genzyme shows some sparkle at investors' conference. Investors, take note.
The Motley Fool February 18, 2005 John Bluis	Genzyme's Acquisitions Pay Off With some of this biotech's major decisions coming to fruition, shareholders can have more confidence that management can deliver on its promises.
The Motley Fool September 6, 2006 Brian Lawler	AnorMED's Tumultuous Year A takeover attempt follows management shakeups at the biopharmaceutical firm. Investors, take note.
The Motley Fool October 29, 2007 Brian Lawler	Genzyme Gets It Together Genzyme may not engender as much investor excitement as Carl-Icahn-acquisition-hyped biopharmas. But its diverse pipeline, and the strong performance it delivers quarter after quarter, deserve some investor attention.
The Motley Fool July 23, 2009 Brian Orelli	This Too Shall Pass ... Like a Kidney Stone Demand outstrips supply? Boo-hoo. Lowered guidance because a company can't make enough to keep up with demand. Example: Genzyme
The Motley Fool April 13, 2007 Brian Lawler	Genentech Is Still Healthy The biopharma powerhouse announces its first-quarter financial results. Investors, take note.
The Motley Fool September 13, 2010 Brian Orelli	When All Else Fails, Sell! Genzyme has no other choice.
The Motley Fool July 18, 2005 Stephen D. Simpson	Rare Diseases Mean Solid Growth for Genzyme Genzyme doesn't target well-known diseases, but then neither does the competition. Valuing these shares is a bit tricky.
The Motley Fool October 4, 2010 Ryan McBride	Sanofi-Aventis Launches Hostile Takeover Bid for Genzyme The French drug giant makes a tender offer of $69 a share.
The Motley Fool March 21, 2007 Ryan Fuhrmann	Adobe's Acrobatic Quarter: Fool by Numbers The creative software firm released first-quarter 2007 results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool March 2, 2004 David Nierengarten	Genzyme's Oncology Acquisitions The biotech gobbles up two smaller firms for their cancer treatment pipelines.
The Motley Fool July 23, 2007 Brian Lawler	Acquisitive Ways Paying Off for Genzyme A recently acquired drug yields positive study results. Genzyme investors, take note.
The Motley Fool July 26, 2010 Ryan McBride	How Much Would You Pay for Genzyme? Speculation has erupted over the potential outcome of reported M&A talks between the Cambridge, MA-based biotech powerhouse Genzyme and the French drug giant Sanofi-Aventis
The Motley Fool November 18, 2010 Brian Orelli	Genzyme: Slimmed Down, Gussied Up But will anyone buy it?
The Motley Fool May 3, 2007	BioMarin's Big Moves: Fool by Numbers The pharmaceutical released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool August 30, 2010 Ryan McBride	Genzyme Shoots Down Sanofi-Aventis's Buyout Offer Genzyme would be a prize for several major drug companies in need of new revenue streams.
Chemistry World October 5, 2010 Andrew Turley	Sanofi hostile move for Genzyme Sanofi-Aventis has taken its $69-per-share ( 44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board.
The Motley Fool November 19, 2009 Brian Orelli	This Stock Is a Train Wreck Genzyme's string of missteps has investors nervous.
The Motley Fool August 8, 2007 Brian Lawler	Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline.
The Motley Fool December 13, 2010 Brian Orelli	Yep, We Still Want to Lowball You sanofi-aventis still wants investors shares in Genzyme, but it's not willing to step up the price.
The Motley Fool May 26, 2010 Brian Orelli	Is This 4,000-Liter Bioreactor Half-Full? Or half-empty? Only time will tell for Genzyme.
The Motley Fool January 5, 2010 Brian Orelli	A Deal Manufactured by Necessity Genzyme gets some help from a new friend.
The Motley Fool February 17, 2011 Brian Orelli	What Sanofi-Genzyme Means for the Rest of Biotech This is no time to celebrate.
The Motley Fool July 26, 2010 Brian Orelli	Beleaguered Biotech for Sale by Owner. Maybe. Will Genzyme's management sell before the turnaround is complete?
The Motley Fool November 24, 2010 Brian Orelli	Yay! We Don't Have to Pay an 18.5% Penalty Genzyme moves one step closer to a comeback. The company announced today that it had met its deadline for moving the fill-and-finish activities for drugs sold in the U.S. out of its beleaguered Allston, Mass., plant.
The Motley Fool April 20, 2007	Armor's Profits Pierced: Fool by Numbers The maker of military vehicles and armor released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool March 3, 2009 Brian Orelli	A Tale of 2 Weeks It's been a busy two weeks at Genzyme as two nasty notes from the FDA follow two approvals.
The Motley Fool May 5, 2005 Brian Gorman	Boning Up at Genzyme In its latest acquisition, the biotech claims a line of products from Bone Care. But is the company spreading itself a little too thin?
The Motley Fool September 23, 2010 Ryan McBride	Genzyme Boss Not Ready to Sell to Sanofi The Dutch-born CEO is known for his tight control of decisions made at Genzyme, even to a fault.
The Motley Fool February 12, 2009 Brian Orelli	Cruising, but Ready to Take Off Genzyme's in wait-and-see mode.
The Motley Fool May 9, 2006 Seth Jayson	Blackboard Chalks It Up: Fool by Numbers The company released first-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool February 17, 2010 Brian Orelli	Execute Well or You're Out Genzyme needs to show investors that it can rebuild.
The Motley Fool March 31, 2010 Brian Orelli	A Double-Digit Jump? For That? Isis' drug discovery license doesn't look too exciting to me.
The Motley Fool October 28, 2010 Brian Orelli	This Takeover's Going Nowhere Fast The Sanofi-Genzyme Drama, Take 37.
The Motley Fool July 7, 2010 Brian Orelli	That's Gotta Hurt: Recommending the Competition Supply constraints continue to plague Genzyme.
The Motley Fool September 28, 2007 Brian Lawler	Bioenvision Shareholder Battle Genzyme announces that it "cannot and will not" raise its $5.60-a-share bid for Bioenvision before shareholders go to vote on its proposed takeover. Investors, take note.
The Motley Fool February 23, 2010 Brian Orelli	Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year.
The Motley Fool March 3, 2011 Ryan McBride	With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players.
The Motley Fool October 4, 2010 Brian Orelli	That's No Way to Make Friends Sanofi goes hostile on Genzyme.
The Motley Fool April 23, 2007	Fueled by Manpower: Fool by Numbers The staffing firm released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...